On June 30, 2026, ResMed Inc. entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in cash. The transaction is expected to close in the first quarter of fiscal year 2027. MatrixCare generated approximately $220 million in revenue and $55 million in non-GAAP operating profit for fiscal year 2026. ResMed plans to use net proceeds for general corporate purposes and to return capital to shareholders via an accelerated share repurchase program. Additionally, the company noted that its Noctrix acquisition is expected to add $30 million in revenue but reduce non-GAAP diluted EPS by $0.20 in fiscal year 2027. ResMed operates in the healthcare industry, providing medical devices and software for respiratory and sleep apnea care.